This page contains a Flash digital edition of a book.
Veale_edit.qxp 1/10/07 12:18 Page 21
Spondyloarthropathies
How to Treat Both Joint and Skin in Psoriatic Arthritis
a report by
Laure Brulhart
1
and Douglas J Veale
1,2
1. Department of Rheumatology, St Vincent’s University Hospital, Dublin; 2. The Conway Institute of Biomedical Biomolecular Research and
Dublin Academic Health Centre, University College Dublin
Psoriatic arthritis (PsA) is a chronic and disabling inflammatory alternative.
9,10
A number of reports of NSAIDs resulting in a flare or
arthritis that affects 0.2–1% of the population
1
and 6–42% of psoriasis worsening of skin psoriasis have led to some patients being reluctant
patients.
2
It may present as a symmetrical polyarthritis indistinguishable to take them continuously.
11
from rheumatoid arthritis (RA), although distal interphalangeal joints
and the small joints of the feet are more often involved. It may also Even without randomised controlled trials (RCTs), expert opinion is
present as an asymmetrical arthritis, often oligoarticular in nature.
3
PsA that steroid injection may be the most appropriate option for
is classified as spondylarthropathy with inflammatory spinal persistent monoarthritis,
11
enthesopathy
12
and dactylitis.
13
Systemic
manifestations, enthesopathy, dactylitis and uveitis occurring steroids may be useful for rapid peripheral symptom release when PsA
commonly. PsA is a progressive disorder in 11–62% of patients, patients fail to respond or do not tolerate NSAIDs; however, they
associated with erosions, deformity and reduced function.
4
Quality of should be used with caution because withdrawal may trigger acute
life evaluated with health-related EuroQol (EQ-5D) is similarly reduced flare in pustular psoriasis.
14
compared with RA patients.
5
Disease-modifying Antirheumatic Drugs
The effectiveness of DMARDs has been evaluated in only a few
RCTs, but they remain the first choice for long-term management of
Recent research on immuno- PsA. Only two small randomised, placebo-controlled studies on a
pathological mechanisms has
total of 58 patients have been conducted into methotrexate (MTX),
the most frequently used DMARD.
15
highlighted novel findings shared
between psoriasis and psoriatic
In the first study, a single parenteral dose of MTX was associated with
significant improvement in joint tenderness, range of motion, skin
arthritis, such as angiogenesis and
lesions and sedimentation rate.
16
Gastrointestinal and haematological
tumour necrosis factor α.
adverse reactions were high – gastrointestinal: 76%; leukopaenia:
33%; two deaths – which is probably due to the method of
administration. The second study showed small oral dosages of MTX
(7.5–15mg/week) to be effective in terms of physician’s global disease
Recent research on immunopathological mechanisms has highlighted assessment and psoriasis skin surface area, but other end-points – such
novel findings shared between psoriasis and PsA, such as angiogenesis as joint tenderness, swelling or duration of morning stiffness – did not
and tumour necrosis factor α (TNFα).
6
However, the management of improve;
17
however, this study used low dosages of MTX and had a
psoriasis and PsA depends on the clinical presentation and includes short follow-up (12 weeks) and small patient numbers (n=37). In
topical therapies for skin disease and non-drug therapy, physiotherapy
and rehabilitation, systemic and injectable anti-inflammatory
Laure Brulhart is a Research Fellow in Rheumatology in the
treatment and disease-modifying antirheumatic drugs (DMARDs) for
Department of Rheumatology, St Vincent’s University
PsA. In this brief review, we will focus on systemic therapies for joint Hospital, Dublin. Her specialist clinical interests are
and skin disease.
musculoskeletal ultrasound and biologic treatment of chronic
inflammatory arthritis. Dr Brulhart graduated from the
University of Geneva Medical School in 2000.
Non-steroidal Anti-inflammatory Drugs and Corticosteroids
Non-steroidal anti-inflammatory drugs (NSAIDs) are useful in the
symptomatic management of PsA patients. NSAIDs appear to be
Douglas J Veale is Adjunct Professor of Medicine in the
Department of Rheumatology, St Vincent’s University
rapidly effective at relieving axial pain and stiffness.
7
In ankylosing
Hospital, and The Conway Institute of Biomedical
spondylitis patients, continuous NSAID administration may reduce Biomolecular Research and Dublin Academic Health Centre,
radiographic progression.
8
NSAIDs may also be useful for
University College Dublin. He is also Director of Research at
The Education and Research Centre, St Vincent’s University
enthesopathy or peripheral oligoarthritis, without disability or evidence
Hospital. Professor Veale’s clinical research interests include
of progressive erosions.
9
However, gastrointestinal side effects limit
early inflammatory arthritis, psoriatic and rheumatoid
arthritis and psoriasis, focusing on immunopathogenesis,
the prescription of this medication. Selective – such as celecoxib – and
hypoxia, angiogenesis and biopharmaceuticals.
relatively selective – such as meloxicam – cyclo-oxygenase 2 (COX-2)
E: douglas.veale@ucd.ie
are associated with a lower risk of bleeding and may be an
© TOUCH BRIEFINGS 2007 21
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99
Produced with Yudu - www.yudu.com